CapitolRadar tracks every publicly disclosed BCRX trade by US congress members and corporate insiders: 4 disclosed trades (3 buys, 1 sells) by 2 tracked traders, from 2023-09-15 to 2026-07-10. Updated daily from official filings.
Want a ping when Congress buys BCRX? Free email alerts on notable disclosed trades — plus a $100,000 fantasy portfolio to play along against three AI traders. Join free
BioCryst Pharmaceuticals, Inc. (BCRX) — Healthcare · Biotechnology, market cap about $2.0B.
CapitolRadar analysis
4 disclosed trades, with buys outnumbering sells 3 to 1
BCRX, BioCryst Pharmaceuticals, Inc., has 4 tracked congressional trades involving 2 distinct traders across the period from September 15, 2023, to July 10, 2026. The activity consists of 3 buys and 1 sell, giving the limited record a net buying tilt by transaction count. This is a small sample, however, so the buy-sell split should not be treated as a broad or persistent pattern.
The activity is also spread unevenly across time. The third quarter of 2023 contains 1 trade, which was the dataset’s only sale. The fourth quarter of 2023 contains 1 buy. The third quarter of 2026 accounts for the remaining 2 trades, both buys. No additional activity is provided for the period between those reported quarters.
2 Cisneros buys lead the named buyer activity
Gilbert Cisneros accounts for 2 of the 3 BCRX buys, with his latest purchase dated July 10, 2026. Josh Gottheimer accounts for 1 buy, dated October 16, 2023. Together, the two named buyers represent all purchases in the supplied record. The facts do not separately identify the trader associated with the single sale, so no seller attribution can be made from this dataset.
3 shared tickers link both BCRX buyers
Both BCRX buyers also purchased CRWD, AMD and MSFT. One of the two also bought ALKS, FERG and MTX. These overlaps provide context on other disclosed purchases, but the sample of just 2 buyers is too small to establish a dependable portfolio pattern or a BCRX-specific signal.
Congressional transaction disclosures can be filed up to 45 days after a trade, creating a lag between activity and public visibility. Reported transaction amounts are generally disclosed as ranges, so any dollar totals derived from them are estimates rather than exact values. Those reporting limitations, combined with only 4 tracked trades, materially constrain interpretation.
Analysis written from the tracked record on 2026-09-11; it is refreshed whenever the underlying numbers change.
Activity by quarter
| Quarter | Disclosed trades | Buys | Sells |
|---|---|---|---|
| 2026 Q3 | 2 | 2 | 0 |
| 2023 Q4 | 1 | 1 | 0 |
| 2023 Q3 | 1 | 0 | 1 |
Who is buying BCRX?
| Trader | Disclosed buys | Last buy | Grade |
|---|---|---|---|
| Gilbert Cisneros | 2 | 2026-07-10 | — |
| Josh Gottheimer | 1 | 2023-10-16 | — |
Disclosed trades in BCRX
| Date | Who | Type | Amount | 30d vs SPY |
|---|---|---|---|---|
| 2026-07-10 | Gilbert Cisneros | buy | $1,001 - $15,000 | — |
| 2026-07-09 | Gilbert Cisneros | buy | $1,001 - $15,000 | — |
| 2023-10-16 | Josh Gottheimer | buy | $1,001 - $15,000 | — |
| 2023-09-15 | Josh Gottheimer | sell | $1,001 - $15,000 | — |
These buyers also bought
Other stocks the tracked buyers of BCRX disclosed buying in the last six months: CRWD (2) · MSFT (2) · AMD (2) · SAIL (2) · ALKS (1) · COMP (1).
About BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. ORLADEYO: An oral serine protease inhibitor designed to manage hereditary angioedema. BioCryst's development pipeline includes several promising candidates: BCX9930: An oral factor D inhibitor in Phase II clinical trials…
Frequently asked questions
Which politicians bought BCRX most?
Gilbert Cisneros leads with 2 disclosed buys, followed by Josh Gottheimer.
How current is this page?
It re-renders from the tracked record on every view and new filings are ingested daily — but STOCK Act disclosures can lag the trade by up to 45 days, so the most recent weeks are always incomplete.
Get alerts when trades like these are disclosed. Free account: fantasy portfolio + email alerts. Premium: a 6-hour head start on every signal.
CapitolRadar tracks publicly disclosed trades (STOCK Act filings and SEC Form 4). Disclosures can lag the trade by up to 45 days. Backtests measure past disclosed buys against the S&P 500 and do not predict future results. Everything on this page is impersonal information for your own research — not investment advice.